Shape Therapeutics
4 articles with Shape Therapeutics
-
Shape Therapeutics to Highlight RNA Editing Technology Platform Advancements in Parkinson’s Disease and the Identification of Novel CNS-targeting AAV Variants at the J.P. Morgan 39th Annual Healthcare Conference
1/11/2021
Shape Therapeutics Inc. (ShapeTX), a next-generation RNA-targeting gene therapy company, announces today the upcoming company presentation at the J.P. Morgan 39th Annual Healthcare Conference by Francois Vigneault, PhD., President and Chief Executive Officer.
-
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Shape Therapeutics Announces Appointment of Gary Fortin as Chief Operating Officer
12/8/2020
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the appointment of Gary Fortin as Chief Operating Officer (COO). Prior to joining ShapeTX, Dr. Fortin was Head of Business Strategy and Operations for the Severe Genetic Disease unit of bluebird bio (NASDAQ:BLUE), where he navigated a portfolio of gene therapy programs through
-
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
12/3/2020
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery platform and results from its first AAV5 variant library in a non-human primate selection campaign.